New triple drug combination shows promise in hepatitis C infected patients

New data demonstrates a high sustained virologic response (SVR) at 12 weeks from the all-oral combination of sofosbuvir/velpatasvir and experimental compound GS-9857 in patients with the hepatitis C virus (HCV).